Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

KU School of Medicine-Wichita Department of Pediatrics and Wesley Children’s Hospital say a groundbreaking treatment for ...

Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics achieved a significant finding in ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics made a pivotal discovery in the field ...

A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

Background: This study aims to identify the hub genes and immune-related pathways in acute myeloid leukemia (AML) to provide new theories for immunotherapy. Methods: We use bioinformatics methods to ...

A phase 3 trial confirms “the potent anti-leukemic effect” of consolidation with allogeneic transplant in older patients with acute myeloid leukemia, according to researchers.

The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from ...

These data are consistent with previous GPS trials. In the Phase 2 study in AML patients in second complete remission, the median overall survival of GPS-treated patients was 21 months versus 5.4 ...

New data suggest venetoclax may offset the negative prognostic impact of short telomeres in patients with chronic lymphocytic ...

In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in ...